You are here

Home » Content

İMMÜNOTERAPİ ALTINDA GELİŞEN OTOİMMÜN HİPOTİROİDİ OLGUSU SUNUMU

Journal Name:

  • Cerrahpaşa Tıp Dergisi

Publication Year:

  • 1999

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Immunotherapy is one of the current treatment modalities used for the therapy of malignant melanoma and various other malignancies. The immunomodulator agents used for immunotherapy have different side effects such as autoimmune thyroid dysfunction. Observation.- A case of metastatic malignant melanoma who developed autoimmune thyroid dysfunction while under chemoimmunotherapy is presented and the side effects of treatment with immunomodulators are discussed.
Bookmark/Search this post with
Abstract (Original Language): 
İmmünoterapi günümüzde malign melanomayı da içerin birçok malign hastalığın tedavisinde kullanılan tedavi yöntemlerinden birisidir. immünoterapide kullanılan immünomodülatörlerin diğer yan etkilerinin yanı sıra otoimmün tiroid fonksiyon bozukluğu gibi yan etkilerinin de olabileceği tanımlanmıştır. Yazımızda metastatik malign melanomalı bir olgumuzda kemoimmünoterapi altında gelişen otoimmün tiroidit nedeniyle immünomodülatör tedavinin yan etkileri irdelenmiştir.
FULL TEXT (PDF): 
PDF icon arastirmax-immunoterapi-altinda-gelisen-otoimmun-hipotiroidi-olgusu-sunumu.pdf
  • 2
179-183
  • Turkish

REFERENCES

References: 

1. Haskell. Melanoma and skin cancer. Cancer treatment. 1992; PX810-822.
2. Burmeister BH, Simithers BM, Poulsen M, McLeod GR, Bryant G, Tricopony L, Thorpe C. Radiation therapy for nodal disease in malignant melanoma. World J Surg 1995; 19: 369-377.
3. Richards JM, Mahta N, Ramming K, Skosey P. Sequiential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Onc 1992; 1338-1343.
4. Khayat D, Giroux B, Berille J, Cour V, Gerard B, Sarkany M, Bertnand P, Bizarre JP. Fotemusine in the treatment of primary brain tumors and metastases. Cancer Invest 1994; 414-420.
5. Klein ES, Davidson B, Apter S, Azizi E, Ben-Ari GY, Total abdominal perfusion in the treatment of abdominal metastatic melanoma. J Surg Oncol 1994; 134-137.
6. Marshall ES, Holdaway KM, Shaw JH, Finlay GJ, Matthews JN. Anticancer drug sensitivity profiles of new and established melanoma cell lines. Oncol Res 1993; 301-309.
7. Garbe C. Chemotherapy and chemoimmunotherapy in dissemimated malign melanoma. Can Res 1993; 291-299.
8. Margolin KA, Doroshow JH, Akman SA, Leong LA, Morgan RJ, Somla G, Raschko J, Pereria C, Yoncmoto L, Ahn C. Phase II trial of CDDP and IFN- in advanced malignant melanoma. J Clin Onc 1992; 1574-1578.
9. Buzaid AC, Legha SS. Combination of chemotherapy with IL-2 and IFN- for the treatment of advanced malignant melanoma. Semin. Oncol.1994; 21: 23-28.
10. Mathe G, Amiel JL, Schwarzenberg L et al. Active immunotherapy for acute lymphoblastic leukaemia. Lancet 1976; 697-699.
11. Mastrangelo MJ, Berd D, Mafuire HC Jr. Current condition and prognosis and prognosis of tumor immunotherapy, a second opinion. Cancer Treat 1984; 68: 207-219.
12. Isaacs A, Lindenmann J. Virus interference. The interferons. Proc R Soc Lond B Biol Sci 1957; 147: 258-267.
13. Steward WE II, Blalock JE, Burke DC et al. Interferon nomenclature. J Immunol 1980; 125: 2353.
14. Roth SM, Foon KA. Alpha interferon in the treatment of haematologic malignancies. Am J Med 1986; 81: 871-882.
15. Fleischmann WR, Klimpel GR, Tyring SK, Voss WR, Baron S. Interferon and cancer, current use and novel approaches. FI Academic Press. 1984; 1-22.
16. Borden EC. Progress toward therapeutic application of interferons. Cancer (Phila) 1984; 54: 1770-1776.
17. Carrel S, Schimid-Kessen A, Giuffre L. Recombinant inerferon-gamma can induce the expression of HLA-DR and DQ on DR negative melanoma celis and enhance the expression of HLA-ABC and tumor associated antigens. Eur J Immunol 1985; 15: 118-123.
18. Smith KA. Interkeukin-2: Inception, impact and implications. Science 1988; 240: 1169-1176.
19. Trichineri J, Parussia B. Biology of disease. Human natural killer cells, biologic and pathologic agents. Lab Invest 1984; 50: 489-513.
20. Rubin JT, Elwood J, Rosenberg SA, Lotze MT. Immunohistochemical correlates of response to recombinant interleukin-2 based immonutherapy in humans. Cancer Res 1989; 49: 7086-7092.
21. Pizzalo G, Chilosi M, Semenzato G. The soluble interleukin-2 receptor in haematological disorders. Br J Haematol 1987; 67: 377-380.
22. Pui CH, Ip SH, Kung P, Dodge RK, et al. High serum interleukin-2 receptor levels are related to advanced disease on a poor outcome in childhood Non-Hodgkin's Lymphoma. Blood 1987; 70: 624-628.
23. Prank A. Biological response madifiers. The new immunotherapy. Cancer Res 1989; 49: 1621-1639.
24. Imura H, Fıkata J, Mon T. Cytokines and endocrine function: an interaction between the immune and neuroendocrine systems. Clinical Endocrinol 1991; 35: 107-115.
25. Eberlein TJ, Schoof DD, Jung SE, et al. A new regimen of interleukin-2 and lymphokine activated killer cells. Efficacy without signifıcant toxicity. Arch Int Med 1988; 148: 2571-2576.
26. Dutcher JP, Creekmore S, Weiss GR. et al. A phase II study of interleukin-2 and lymphokine activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol 1989; 7: 477-485.
27. Kung AW, Lai CL, Wong KL, Tam CF. Thyroid functions in patients treated with interleukin-2 and lymphokine activated killer cells. Q J Med 1982; 33-42.
28. Mier JW, Vachino J, Van der Meer JW et al. Induction of circulating tumor necrosis factor as the mechanism for the febrile response to interleukin-2 in cancer patient. J Clin Immunol 1988; 8: 426-436.
29. Harold I, Wanebo MD, Ron Pace BS, Hargett S, Katz D, Sando J. Production of and response to interleukin-2 in peripheral blood lymphocytes of cancer patients. J Clin Immunol 1986; 57: 656-662.
30. Rosenberg SA, Yanelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Scipp CA, Einhom JH, White DE. Treatment of patients with metastatic melanoma with autologous tumor infiltrating lymphocytes and IL-2. J Nat Cancer Inst 1994; 86: 1159-1166.
31. Sanol M, Parkinson DR. Clinical applications of IL-2. Oncology Huntingt 1994; 8: 61-67.
32. Atkins M, Mier JW, Demchak P et al. Thyroid dysfunction following IL-2 therapy. ProcASCO 1990; 9: 186.
33. Tartour E, Schlumberger M, Dorval T, Baudin E, Fridman WH. Endocrine involvement in immunotherapy. Ann Endocrinol 1995; 56: 143-148.
34. Uchida K, Matsui A, Nakano S, Kigoshi T, Morimoto S. Painless Thyroiditis occuring during long term interferon alpha in a patient with chronic active hepatitis. South Med J 1996; 81-83.
35. Weijl NI, Van der Harst D, Brand A, Kooy Y, Van Luxemburg S, Schroder W, Lentjes E, Van Rood JJ, Clenton FJ, Osanto S. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. L Clin Oncol 1993; 1376-1383.
36. Weisel M, Templ E, Gisslinger H. Interferon alpha induced disorders of thyroid function. A retrospective analysis of the literature and personal experience. Acta Med Austriaca (Abst.) 1995; 22: 1-5.
37. Corssmitt EP, Heylingenberg R, Endert E, Sauerwein HP, Romiwn JA. Acute efeects of interferon alpha administration of thyroid hormone metabolism in healthy men. J Clin Endocrinol Metabl 1995; 80: 3140-3141.
38. Chedin P, Chanson P, Durenteau L, Guillesseau PJ, Lubetzki J. Disthyroidism in patients treated with interferon alpha. Presse Med 1994; 1659-1663.
39. Scolza S, Gengaro A, Boccoli G, et al. Primary hypothyroidism associated with interleukin-2 and interferon alpha thrapy of melanoma and renal carcinoma. Eur J Cancer 1990; 26: 1152-1156.
40. Pichert G, Jost LM, Zobeli L, et al. Thyroiditis after treatment with interleukin-2 and interferon alpha. Br J Cancer 1990; 62: 102-104.

Thank you for copying data from http://www.arastirmax.com